




# Efficacy and Safety of Stents in the Treatment of Fistula After Bariatric Surgery: a Systematic Review and Meta-analysis

Ossamu Okazaki<sup>1</sup>  · Wanderley M. Bernardo<sup>1</sup> · Vitor O. Brunaldi<sup>1</sup> · Cesar C. de Clemente Junior<sup>1</sup> · Maurício K. Minata<sup>1</sup> · Diogo T. H. de Moura<sup>1</sup> · Thiago F. de Souza<sup>1</sup> · Josemberg Marins Campos<sup>2</sup> · Marco Aurélio Santo<sup>3</sup> · Eduardo G. H. de Moura<sup>1</sup>

© Springer Science+Business Media, LLC, part of Springer Nature 2018

## Abstract

Fistula development is a serious complication after bariatric surgery. We performed a systematic review and meta-analysis to assess the efficacy of fistula closure and complications associated with endoscopic stent treatment of fistulas, developed after bariatric surgeries, particularly Roux-en-Y gastric bypass (RYGB) and gastric sleeve (GS). Studies involving patients with fistula after RYGB or GS and those who received stent treatment only were selected. The analyzed outcomes were overall success rate of fistula closure, mean number of stents per patient, mean stent dwelling time, and procedure-associated complications. Current evidence from identified studies demonstrates that, in selected patients, endoscopic stent treatment of fistulas after GS or RYGB can be safe and effective.

**Keywords** Sleeve · Bypass · Bariatric · Stent · Fistula

## Introduction

According to the World Health Organization, the worldwide prevalence of obesity has more than doubled since 1980. In 2014, > 1.9 billion adults aged  $\geq 18$  years were overweight, of which > 600 million were obese [1]. Obesity is an important risk factor for some cancers and osteoarticular and cardiovascular diseases, particularly acute myocardial infarction and

stroke, which were the main causes of death in 2012 [1]. Fortunately, controlling comorbidities such as hypertension and diabetes mellitus by treating obesity is possible, thereby reducing morbidity and mortality among patients [2–4].

Surgery is the most effective long-term treatment for patients with morbid obesity and thus has been increasingly performed in recent years [4]. According to the American Society for Metabolic and Bariatric Surgery [5], the

---

✉ Ossamu Okazaki  
ossamuok@gmail.com

Wanderley M. Bernardo  
wmbernardo@usp.br

Vitor O. Brunaldi  
vbrunaldi@gmail.com

Cesar C. de Clemente Junior  
cesarecapel@yahoo.com.br

Maurício K. Minata  
mauriciominata@hotmail.com

Diogo T. H. de Moura  
dthmoura@hotmail.com

Thiago F. de Souza  
tsouzahc@gmail.com

Josemberg Marins Campos  
josembergcampos@gmail.com

Marco Aurélio Santo  
santomarco@uol.com.br

Eduardo G. H. de Moura  
eduardoghdemoura@gmail.com

<sup>1</sup> Gastrointestinal Endoscopy Unit, Hospital das Clinicas, University of São Paulo Medical School, Dr. Arnaldo Av, 255., São Paulo 01246-903, Brazil

<sup>2</sup> Department of Surgery, University of Pernambuco, Recife, Pernambuco, Brazil

<sup>3</sup> Bariatric and Metabolic Surgery Unit, Hospital das Clinicas, University of Sao Paulo Medical School, São Paulo, Brazil

approximate number of bariatric surgeries performed in the USA was 179,000 in 2013; 193,000 in 2014; and 196,000 in 2015. Gastric sleeve (GS) was the most frequent procedure (53.8%), followed by Roux-en-Y gastric bypass (RYGB) (23.1%), revision surgery (13.6%), gastric banding (5.7%), and duodenal switch (0.6%). Although these procedures are considered safe, the increasing number of procedures is associated with a significant number of related complications [6].

Fistula development is one of the most serious complications, with incidences ranging from 1 to 8.3% after laparoscopic RYGB and from 0 to 7% after GS [7–14]. Until recently, fistula was preferably treated with surgery; however, surgery is associated with higher morbidities than currently available, less invasive therapeutic options [15–18].

Some studies have reported the successful nonsurgical conservative treatment of fistulas after bariatric surgery [19–21]. These less invasive therapeutic options include several endoscopic techniques. The closure of fistulas, developed after bariatric surgery, using metal clips alone or combined with other endoscopic procedures has been described [22–26].

The use of fibrin glue and endoscopic drainage has also been reported for endoscopically treating fistulas [27–30]. Furthermore, the effective treatment of fistulas, developed after bariatric surgery, with stent placement has been described [31–38].

In 2016, the European Society of Gastrointestinal Endoscopy, in its guidelines, indicated that temporary stent placements can be considered for treating fistulas or benign esophageal perforations (strong recommendation; low quality of evidence) [39]. Furthermore, the American Society for Metabolic and Bariatric Surgery recommends stent placement, among other endoscopic techniques, for treating fistulas developing after bariatric surgery [40].

This study aimed to assess the efficacy of fistula closure and the complications associated with endoscopic stent treatment of fistulas, which developed after bariatric surgeries, particularly GS and RYGB.

## Materials and Methods

### Data Sources and Searchers

This systematic review and meta-analysis was conducted according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA), was approved by the Research Ethics Committee of the Clinics Hospital of the School of Medicine of the University of São Paulo, and was registered in the international database PROSPERO ([www.crd.york.ac.uk/prospere](http://www.crd.york.ac.uk/prospere); protocol no: CRD42016050143) [41]. For this type of study, formal consent is not required.

Studies were identified by searching electronic databases, namely MEDLINE, Embase, Cochrane, and LILACS, and reviewing the selected studies' bibliographic references. The last search was conducted in October 2016. The search strategy for MEDLINE was “(Bariatric \* OR metabolic surgery OR stomach stapling OR gastroplasty OR sleeve OR bypass) AND (leak \* or fistula \*).”

### Study Selection

Randomized clinical trials, observational cohort studies, and case series were considered eligible. Only full-text articles were selected. Inclusion and exclusion criteria are summarized below:

#### Inclusion criteria

- Studies that included patients with fistula after RYGB or GS
- Studies wherein stent placement was the only endoscopic method for treating fistula

#### Exclusion criteria

- Studies wherein patients underwent bariatric surgery using techniques other than GS or gastric bypass
- Studies without a clear description of the endoscopic treatment
- Studies that included patients who underwent a combined endoscopic treatment

The extracted data were associated with the (1) characteristics of the studies, namely inclusion and exclusion criteria; (2) characteristics of the population; (3) type of intervention, considering the technique and stent type used; and (4) different outcomes. The extracted data were divided into two groups: fistulas after RYGB and those after GS. Comprehensive Meta-Analysis software (Englewood, NJ) was used for meta-analysis of the data and the risk of bias was assessed using the Critical Appraisal Checklist for Case Series of the Joanna Briggs Institute [42].

### Data Synthesis and Analysis

Patients' demographic data (e.g., age, BMI, fistula location, and time to diagnosis) were analyzed for studies with available data. Regarding time to diagnosis, fistulas were classified as acute ( $\leq 7$  days), early (between 1 and 6 weeks), late (between 6 and 12 weeks), and chronic ( $> 12$  weeks) [43].

## Outcomes

The primary outcome was the success rate of fistula closure, defined as the percentage of patients with successful fistula closure, as confirmed by contrast X-ray and/or digestive endoscopy, after stent placement.

The secondary outcomes were rate of stent migration, mean stent dwelling time, mean number of stents per patient, and mean period to fistula diagnosis.

## Results

### Search Results

The literature search yielded 5706 studies in MEDLINE and 3768 studies in the remaining databases. After excluding duplicated studies, 8877 studies were preselected. Of 8877 studies, 28 fulfilled the inclusion criteria and the criteria for quantitative and qualitative analysis and thus


were included in this review (Fig. 1). All selected studies were published between 2006 and 2016 (Table 1). No prospective, comparative, and randomized studies were found in the literature. Therefore, only case series studies were included.

The outcomes were assessed in two subgroups: fistulas after GS and those after RYGB. For the analysis of each outcome, only studies with sufficient data were included. Seven studies were included in both subgroups.

Twenty-four studies, having 187 patients, were included in the GS group. The mean age of the patients was  $42.94 \pm 0.46$  years, mean BMI was  $40.04 \pm 0.38$  kg/m<sup>2</sup>, overall success rate was 72.8% (Fig. 2), mean number of stents per patient was  $1.4 \pm 0.03$ , mean period for fistula diagnosis was  $3.35 \pm 0.28$  days after surgery, and mean stent dwelling time was  $48.77 \pm 0.58$  days. The stent migration rate was 28.2% considering all studies (Fig. 3).

The selected studies were subsequently divided into those that only used stents for specifically treating post-bariatric surgery complications and those that used ordinary

Fig. 1 Flow diagram



**Table 1** Search results. *FCSEMS* fully covered self-expandable stent, *PCSEMS* partially covered self-expandable stent

Studies			
Study	Population	Surgery	Stent
Rebibo L, 2016	9	Sleeve	Hanarostent
van Wezenbeek MR, 2016	12	Sleeve/bypass	Hanarostent
Quezada N, 2015	29	Sleeve/bypass	FCSEMS
Périssé LG, 2015	29	Sleeve/bypass	FCSEMS
Fishman S, 2015	26	Sleeve	Hanarostent ou Megastent
Matlok M, 2015	3	Sleeve	Wallflex
Moon RC, 2015	6	Sleeve	–
Juza RM, 2015	5	Sleeve	Wallflex or Alimax-E
Liu S.Y.-W. 2015	2	Sleeve	Megastent
Alazmi W, 2014	17	Sleeve	Ultraflex + Polyflex
Galloro G, 2014	4	Sleeve	Megastent
Aras A, 2014	3	Sleeve	Uncovered biodegradable stent
Leenders BJ, 2013	9	Sleeve/bypass	Hanarostent or Endoflex
Freedman J, 2013	35	Bypass	Danis Stent
Simon F, 2013	9	Sleeve	Hanarostent
El Mourad H, 2013	28	Sleeve/bypass	Ultraflex + Polyflex
Fischer A, 2013	2	Sleeve	PCSEMS
Marr B, 2012	4	Sleeve	Wallflex
Yimcharoen P, 2011	8	Sleeve/bypass	Alimax-E or Evolution or Ultraflex or Polyflex
de Aretxabala X, 2011	4	Sleeve	FCSEMS
Inbar R, 2011	3	Sleeve	SX-ELLA
Tan JT, 2010	8	Sleeve	FCSEMS
Blackmon SH, 2010	10	Sleeve/bypass	Alimax-E stent
Nguyen NT, 2010	3	Sleeve	Allimax-E or Wallflex
Casella G, 2009	3	Sleeve	Ultraflex
Edwards CA, 2008	6	Bypass	Polyflex
Fukumoto R, 2007	3	Sleeve/bypass	Polyflex
Salinas A, 2006	17	Bypass	Ultraflex

esophageal stents. The migration rates in the former and latter subgroups were 31.5 and 27.1%, respectively.

None of the included studies provided data regarding the fistula size. Thirteen studies provided data regarding the fistula location; of 90 patients, 94.4% had fistula in the proximal third of the residual stomach, 4.4% in the middle third, and 1.1% in the distal third.

Fifteen studies provided data regarding the time to fistula diagnosis; of 92 patients, 48.91% had acute fistula (1–7 days after surgery), 34.78% had early fistula (1–6 weeks after surgery), 6.52% had late fistula (6–12 weeks after surgery), and 8.7% had chronic fistula [43]. None of the evaluated studies reported perforation cases. Bleeding requiring additional endoscopic treatments was reported for two patients (1.06%).

Eleven studies, having 108 patients, were included in the RYGB group. The mean age was  $42.96 \pm 0.65$  years, and the mean BMI was  $43.48 \pm 0.68$  kg/m<sup>2</sup>. The overall success rate was 76.1% (Fig. 4), stent migration rate was 30.5% (Fig. 5),

mean number of stents per patient was  $1.28 \pm 0.092$ , and mean stent dwelling time was  $42.83 \pm 1.91$  days. No study provided data regarding the fistula size; therefore, calculating the mean time to fistula diagnosis was not possible.

Only three studies provided data on the time to fistula diagnosis; of 17 patients, 52.82% had acute fistula (1–7 days after surgery), 35.29% had early fistula (1–6 weeks after surgery), no patient had late fistula (6–12 weeks after surgery), and 5.88% had chronic fistula [43]. Two cases (1.85%) of perforation were reported among the included studies, and there were no reported cases of significant bleeding caused by the procedure.

## Discussion

Although fistula development after bariatric surgery is rare, it can significantly increase patient morbidity and mortality [44,




Fig. 2 Gastric sleeve: Forrest plot showing the overall success rate of fistula closure

45]. The obesity epidemic and elevated number of bariatric procedures have increased the number of cases of fistulas developing after GS and RYGB [1, 5].

The pathophysiology of fistulas developing after bariatric surgery is multifactorial and can be divided into ischemic and/or mechanical (staple failure, tension in the anastomosis or along the staple line, hematoma, and distal stenosis). In both situations, intraluminal pressure appears to exceed tissue

resistance along the staple line or anastomosis, leading to fistula formation [46–49].

Treatment of fistulas developing after bariatric surgery is challenging and complex. The use of broad-spectrum antibiotics, proton pump inhibitors, fluid collection drainage (via surgery, guided by X-ray or endoscopy), and nutritional support are essential for initially stabilizing these patients. Different definitive treatments, including surgical and/or




Fig. 3 Gastric sleeve: Forrest plot showing the mean stent migration rate




Fig. 4 Roux-en-Y gastric bypass: Forrest plot showing the overall success rate of fistula closure

endoscopic treatment, can be performed in acute and chronic fistula cases [50–52].

In acute and early fistula cases, surgical intervention with cavity drainage and an attempt of primary fistula repair with suture or materials such as biological glue can be performed in clinically unstable patients, but the recurrence rates are high. Moreover, in clinically stable patients with acute and early fistulas, nonsurgical, less invasive strategies may be used. After adequately draining the collected fluid via endoscopy or guided X-ray, different endoscopic treatments such as endoscopic suture, placement of metal clips, fibrin glue, or stents may be used. Among the endoscopic treatments, stent placement has been gaining importance, and several studies [31–38] have reported high success rates.

Stent placement reduces intraluminal pressure, considered to be the major cause of fistula occurrence and development. The exclusion of the fistula site reduces peritoneal contamination by esophagogastric and enteric secretions and accelerates the healing process. Moreover, the exclusion of the fistula site allows the early return to oral or enteral feeding, thereby avoiding prolonged periods of parenteral nutrition [53].

In this meta-analysis, stent placement was effective for treating fistulas in both the GS and RYGB groups, with

success rates of 73 and 76.1%, respectively, and a low number of stents per patient.

Partially or fully covered metal stents and self-expandable plastic stents are most frequently used for treating complications developing after bariatric surgery. In theory, partially covered metal stents should minimize the risk for migration. Partially covered metal stents reportedly have a lower rate of migration than fully covered metal stents and plastic stents when used for treating esophageal perforations [54]. However, to our knowledge, to date, no studies have demonstrated the superiority of a specific type of benign stent for treating fistulas after bariatric surgery. Although these stent types were used in the studies included in the current review, performing a subgroup analysis to evaluate outcomes of each stent type was not possible because of insufficient data provided in the studies.

Despite potential benefits of stent placement in managing fistulas, several complications associated with the procedure have been reported; bleeding and perforation are the most severe. However, this meta-analysis revealed that stents were well tolerated and resulted in a low rate of severe complications in the RYGB and GS groups. There were no reported perforation cases in the GS group and only 1% of patients had




Fig. 5 Roux-en-Y gastric bypass: Forrest plot showing the mean stent migration rate

significant bleeding. In the RYGB group, the rate of perforation was only 1.85%, and there were no reported cases of significant bleeding.

However, stent migration remains a challenge. The rate of stent migration was high in both the groups (GS group, 28%; RYGB group, 30.6%). The occurrence of migration delays fistula closure, increases the number of endoscopic procedures, and, consequently, increases the likelihood of severe adverse events.

Several alternatives, including stent fixation with placement of metal clips or endoscopic suture, have been reported for preventing migration [55–58]. However, additional studies are warranted to recommend the routine use of these procedures.

In this context, novel stent types, including extra-long fully covered self-expandable metal stents (length, 18–24 cm), have been developed for treating complications developing after GS; these stents should minimize the risk for migration. The proximal stent portion is placed in the mid-esophagus, and the distal portion is placed in the distal segment or first duodenal portion, thus promoting total gastric exclusion. Furthermore, a bigger diameter (22–28 mm) combined with a softer and more malleable material allows a more precise adaptation to the post-GS anatomy [59].

This meta-analysis demonstrated that the migration rate was higher in the subgroup of stents that were specifically designed for complications developing after bariatric surgery than in the subgroup of esophageal stents. This may be explained by the small number of studies included in the former subgroup (four studies) and by the fact that one of the studies reported a migration rate different from the other three studies (80%), significantly increasing the migration rate in this subgroup. Moreover, the absence of comparative studies prevented inferring the superiority of one stent over the other.

Studies [43, 60] have reported a low success rate of therapies wherein stents were used for treating chronic fistulas. Assessing the efficacy of stenting in each subgroup according to the time of fistula presentation is necessary. Results generally would indicate the use of this method more precisely; however, unavailability of data prevented this analysis.

The greatest challenge of the current review was data extraction because of the high heterogeneity among the studies and the lack of sufficient data. Moreover, there was high heterogeneity among patients, fistula characteristics, and types of stents used among the selected studies.

Most studies did not provide data regarding the fistula location, size, and time to diagnosis. Furthermore, the use of endoscopic techniques combined with stent placement without a detailed description of the procedures was commonly observed among the selected studies. These factors prevented a more detailed evaluation of the subgroups and hindered the collection of valuable data regarding important parameters such as the best type of stent to be used or whether stent placement was beneficial for treating chronic fistulas.

Therefore, further studies are needed to confirm the findings of the current review and to clarify important characteristics of fistulas and stents that result in the best response to endoscopic stent treatment. This would allow a more precise indication of the type of therapy for treating fistulas after bariatric surgery.

In summary, the main limitations of the current review were the lack of randomized clinical trials in the literature. Other limiting factors were the high heterogeneity of the population under study, the lack of sufficient data in the selected studies, and, as a result, the impossibility to perform an individualized analysis of the outcomes according to fistula size, location, time to diagnosis, and type of stents used.

## Conclusion

The results of this systematic review and meta-analysis indicate that, in appropriately selected patients, endoscopic treatment of fistulas after GS or RYGB via stent placement can be safe, with a low rate of severe adverse complications, and effective, with a high success rate of fistula closure.

## Compliance with Ethical Standards

**Conflict of Interest** The authors declare that they have no conflict of interest.

**Ethical Approval Statement** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Informed Consent Statement** Informed consent does not apply for this study.

## References

1. WHO | Obesity and overweight. Guideline: sugar intake for adults and children. <http://www.who.int/mediacentre/factsheets/fs311/en/>. Published 2016. Accessed 24 Oct 2016.
2. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R, Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity executive summary complete guidelines available at <https://www.aace.com/publications>. *Endocr Pract* 2016;22(7):842–884. <https://doi.org/10.4158/EP161356.ESGL>.
3. Meijer RI, van Wagenveld BA, Siegert CE, et al. Bariatric surgery as a novel treatment for type 2 diabetes mellitus: a systematic review. *Arch Surg*. 2011;146(6):744–50. <https://doi.org/10.1001/archsurg.2011.134>.

4. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. *JAMA*. 2004;292(14):1724–37. <https://doi.org/10.1001/jama.292.14.1724>.
5. American Society for Metabolic and Bariatric Surgery. Estimate of bariatric surgery numbers—American Society for Metabolic and Bariatric Surgery. [www.asbms.org](http://www.asbms.org). <https://asbms.org/resources/estimate-of-bariatric-surgery-numbers>. Published 2014.
6. Rausa E, Bonavina L, Asti E, et al. Rate of death and complications in laparoscopic and open Roux-en-Y gastric bypass. A meta-analysis and meta-regression analysis on 69,494 patients. *Obes Surg*. 2016;26(8):1956–63. <https://doi.org/10.1007/s11695-016-2231-z>.
7. Podnos YD, Jimenez JC, Wilson SE, et al. Complications after laparoscopic gastric bypass: a review of 3464 cases. *Arch Surg*. 2003;138(9):957–61. <https://doi.org/10.1001/archsurg.138.9.957>.
8. Biertho L, Steffen R, Ricklin T, et al. Laparoscopic gastric bypass versus laparoscopic adjustable gastric banding: a comparative study of 1,200 cases. *J Am Coll Surg*. 2003;197(4):536–44-5. [https://doi.org/10.1016/S1072-7515\(03\)00730-0](https://doi.org/10.1016/S1072-7515(03)00730-0).
9. Fernandez AZ, DeMaria EJ, Tichansky DS, et al. Experience with over 3,000 open and laparoscopic bariatric procedures: multivariate analysis of factors related to leak and resultant mortality. *Surg Endosc*. 2004;18(2):193–7. <https://doi.org/10.1007/s00464-003-8926-y>.
10. Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y-500 patients: technique and results, with 3–60 month follow-up. *Obes Surg*. 2000;10(3):233–9. <https://doi.org/10.1381/096089200321643511>.
11. Al-Sabah S, Ladouceur M, Christou N. Anastomotic leaks after bariatric surgery: it is the host response that matters. *Surg Obes Relat Dis*. 2008;4(2):152–7-8. <https://doi.org/10.1016/j.soard.2007.12.010>.
12. Papasavas PK, Hayetian FD, Caushaj PF, et al. Outcome analysis of laparoscopic Roux-en-Y gastric bypass for morbid obesity. The first 116 cases. *Surg Endosc*. 2002;16(12):1653–7. <https://doi.org/10.1007/s00464-002-8531-5>.
13. Nguyen NT, Goldman C, Rosenquist CJ, et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. *Ann Surg*. 2001;234(3):279–89-91. <http://www.ncbi.nlm.nih.gov/pubmed/11524581>
14. Higa KD, Ho T, Boone KB. Laparoscopic Roux-en-Y gastric bypass: technique and 3-year follow-up. *J Laparoendosc Adv Surg Tech A*. 2001;11(6):377–82. <https://doi.org/10.1089/10926420152761905>.
15. Marshall JS, Srivastava A, Gupta SK, et al. Roux-en-Y gastric bypass leak complications. *Arch Surg*. 2003;138(5):520. <https://doi.org/10.1001/archsurg.138.5.520>.
16. Durak E, Inabnet WB, Schroppe B, et al. Incidence and management of enteric leaks after gastric bypass for morbid obesity during a 10-year period. *Surg Obes Relat Dis*. 2000;4(3):389–93. <https://doi.org/10.1016/j.soard.2007.11.011>.
17. Jacobsen HJ, Nergard BJ, Leifsson BG, et al. Management of suspected anastomotic leak after bariatric laparoscopic Roux-en-y gastric bypass. *Br J Surg*. 2014;101(4):417–23. <https://doi.org/10.1002/bjs.9388>.
18. Lee S, Carmody B, Wolfe L, et al. Effect of location and speed of diagnosis on anastomotic leak outcomes in 3828 gastric bypass cases. *J Gastrointest Surg*. 2007;11(6):708–13. <https://doi.org/10.1007/s11605-007-0085-3>.
19. Ballesta C, Berindoague R, Cabrera M, et al. Management of anastomotic leaks after laparoscopic Roux-en-Y gastric bypass. *Obes Surg*. 2008;18(6):623–30. <https://doi.org/10.1007/s11695-007-9297-6>.
20. Bege T, Emungania O, Vitton VV, et al. An endoscopic strategy for management of anastomotic complications from bariatric surgery: a prospective study. *Gastrointest Endosc*. 2011;73(2):238–44. <https://doi.org/10.1016/j.gie.2010.10.010>.
21. Csendes A, Burdiles P, Burgos AM, et al. Conservative management of anastomotic leaks after 557 open gastric bypasses. *Obes Surg*. 2005;15(9):1252–6. <https://doi.org/10.1381/096089205774512410>.
22. Conio M, Bianchi S, Repici A, et al. Use of an over-the-scope clip for endoscopic sealing of a gastric fistula after sleeve gastrectomy. *Endoscopy*. 2010;42(S 02):E71–2. <https://doi.org/10.1055/s-0029-1215199>.
23. Aly A, Lim HK. The use of over the scope clip (OTSC) device for sleeve gastrectomy leak. *J Gastrointest Surg*. 2013;17(3):606–8. <https://doi.org/10.1007/s11605-012-2062-8>.
24. Winder JS, Kulaylat AN, Schubart JR, et al. Management of non-acute gastrointestinal defects using the over-the-scope clips (OTSCs): a retrospective single-institution experience. *Surg Endosc*. 2016;30(6):2251–8. <https://doi.org/10.1007/s00464-015-4500-7>.
25. Mercky P, Gonzalez J-M, Aimore Bonin E, et al. Usefulness of over-the-scope clipping system for closing digestive fistulas. *Dig Endosc*. 2015;27(1):18–24. <https://doi.org/10.1111/den.12295>.
26. de Moura EGH, Orso IRB, Aurélio EF, et al. Factors associated with complications or failure of endoscopic balloon dilation of anastomotic stricture secondary to Roux-en-Y gastric bypass surgery. *Surg Obes Relat Dis*. 2016;12(3):582–6. <https://doi.org/10.1016/j.soard.2015.11.006>.
27. Donatelli G, Ferretti S, Vergeau BM, et al. Endoscopic internal drainage with enteral nutrition (EDEN) for treatment of leaks following sleeve gastrectomy. *Obes Surg*. 2014;24(8):1400–7. <https://doi.org/10.1007/s11695-014-1298-7>.
28. Pequignot A, Fuks D, Verhaeghe P, et al. Is there a place for pigtail drains in the management of gastric leaks after laparoscopic sleeve gastrectomy? *Obes Surg*. 2012;22(5):712–20. <https://doi.org/10.1007/s11695-012-0597-0>.
29. Sakran N, Goitein D, Raziel A, et al. Gastric leaks after sleeve gastrectomy: a multicenter experience with 2,834 patients. *Surg Endosc*. 2013;27(1):240–5. <https://doi.org/10.1007/s00464-012-2426-x>.
30. Maluf-Filho F, Hondo F, Halwan B, et al. Endoscopic treatment of Roux-en-Y gastric bypass-related gastrocutaneous fistulas using a novel biomaterial. *Surg Endosc*. 2009;23(7):1541–5. <https://doi.org/10.1007/s00464-009-0440-4>.
31. van Wezenbeek MR, de Milliano MM, Nienhuijs SW, et al. A specifically designed stent for anastomotic leaks after bariatric surgery: experiences in a tertiary referral hospital. *Obes Surg*. 2016;26(8):1875–80. <https://doi.org/10.1007/s11695-015-2027-6>.
32. Quezada N, Maiz C, Daroch D, et al. Effect of early use of covered self-expandable endoscopic stent on the treatment of postoperative stapler line leaks. *Obes Surg*. 2015;25(10):1816–21. <https://doi.org/10.1007/s11695-015-1622-x>.
33. Murino A, Arvanitakis M, Le Moine O, et al. Effectiveness of endoscopic management using self-expandable metal stents in a large cohort of patients with post-bariatric leaks. *Obes Surg*. 2015;25(9):1569–76. <https://doi.org/10.1007/s11695-015-1596-8>.
34. Gonzalez J-M, Garces Duran R, Vanbiervliet G, et al. Double-type metallic stents efficacy for the management of post-operative fistulas, leakages, and perforations of the upper gastrointestinal tract. *Surg Endosc*. 2015;29(7):2013–8. <https://doi.org/10.1007/s00464-014-3904-0>.
35. Fishman S, Shnell M, Gluck N, et al. Use of sleeve-customized self-expandable metal stents for the treatment of staple-line leakage after laparoscopic sleeve gastrectomy. *Gastrointest Endosc*. 2015;81(5):1291–4. <https://doi.org/10.1016/j.gie.2014.11.012>.
36. Galloro G, Magno L, Musella M, et al. A novel dedicated endoscopic stent for staple-line leaks after laparoscopic sleeve gastrectomy: a case series. *Surg Obes Relat Dis*. 2014;10(4):607–11. <https://doi.org/10.1016/j.soard.2014.02.027>.



37. Campos JM, Pereira EF, Evangelista LF, et al. Gastrobronchial fistula after sleeve gastrectomy and gastric bypass: endoscopic management and prevention. *Obes Surg*. 2011;21(10):1520–9. <https://doi.org/10.1007/s11695-011-0444-8>.
38. De Moura EGHHTGHHTH, Galvão-Neto MP, Ramos AC, et al. Extreme bariatric endoscopy: stenting to reconnect the pouch to the gastrojejunostomy after a Roux-en-Y gastric bypass. *Surg Endosc*. 2012;26(5):1481–4. <https://doi.org/10.1007/s00464-011-2060-z>.
39. Spaander MCW, Baron TH, Siersema PD, et al. Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. *Endoscopy*. 2016;48(10):939–48. <https://doi.org/10.1055/s-0042-114210>.
40. Kim J, Azagury D, Eisenberg D, et al. ASBMS position statement on prevention, detection, and treatment of gastrointestinal leak after gastric bypass and sleeve gastrectomy, including the roles of imaging, surgical exploration, and nonoperative management. *Surg Obes Relat Dis*. 2015;11(4):739–48. <https://doi.org/10.1016/j.soard.2015.05.001>.
41. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2016;354:i4086. <http://www.ncbi.nlm.nih.gov/pubmed/27444514>
42. The Joanna Briggs Institute. Checklist for case series. In: Joanna Briggs Institute reviewers' manual: 2016 edition; 2016. [http://joannabriggs.org/assets/docs/critical-appraisal-tools/JBI\\_Critical\\_Appraisal-Checklist\\_for\\_Case\\_Series.pdf](http://joannabriggs.org/assets/docs/critical-appraisal-tools/JBI_Critical_Appraisal-Checklist_for_Case_Series.pdf).
43. Rosenthal RJ. International sleeve gastrectomy expert panel consensus statement: best practice guidelines based on experience of >12,000 cases. *Surg Obes Relat Dis*. 2012;8(1):8–19. <https://doi.org/10.1016/j.soard.2011.10.019>.
44. Almahmeed T, Gonzalez R, Nelson LG, et al. Morbidity of anastomotic leaks in patients undergoing Roux-en-Y gastric bypass. *Arch Surg*. 2007;142(10):954–7. <https://doi.org/10.1016/j.soard.2005.03.172>.
45. Podnos YD, Jimenez JC, Wilson SE, Stevens CM, Nguyen NT. Complications after laparoscopic gastric bypass. 2006;138.
46. Baker RS, Foote J, Kemmeter P, et al. The science of stapling and leaks. *Obes Surg*. 2004;14(10):1290–8. <https://doi.org/10.1381/0960892042583888>.
47. Baltasar A, Bou R, Bengochea M, et al. Use of a Roux limb to correct esophagogastric junction fistulas after sleeve gastrectomy. *Obes Surg*. 2007;17(10):1408–10. <http://www.ncbi.nlm.nih.gov/pubmed/18098403>
48. Márquez MF, Ayza MF, Lozano RB, et al. Gastric leak after laparoscopic sleeve gastrectomy. *Obes Surg*. 2010;20(9):1306–11. <https://doi.org/10.1007/s11695-010-0219-7>.
49. Yehoshua RT, Eidelman LA, Stein M, et al. Laparoscopic sleeve gastrectomy—volume and pressure assessment. *Obes Surg*. 2008;18(9):1083–8. <https://doi.org/10.1007/s11695-008-9576-x>.
50. Kumar N, Thompson CC. Endoscopic therapy for postoperative leaks and fistulae. *Gastrointest Endosc Clin N Am*. 2013;23(1):123–36. <https://doi.org/10.1016/j.giec.2012.10.002>.
51. Goenka MK, Goenka U. Endotherapy of leaks and fistula. *World J Gastrointest Endosc*. 2015;7(7):702–13. <https://doi.org/10.4253/wjge.v7.i7.702>.
52. Gonzalez R, Sarr MG, Smith CD, et al. Diagnosis and contemporary management of anastomotic leaks after gastric bypass for obesity. *J Am Coll Surg*. 2007;204(1):47–55. <https://doi.org/10.1016/j.jamcollsurg.2006.09.023>.
53. Shaikh SN, Thompson CC. Treatment of leaks and fistulae after bariatric surgery. *Tech Gastrointest Endosc*. 2010;12(3):141–5. <https://doi.org/10.1016/j.tgie.2010.10.003>.
54. Van Boeckel PGA, Sijbring A, Vleggaar FP, et al. Systematic review: temporary stent placement for benign rupture or anastomotic leak of the oesophagus. *Aliment Pharmacol Ther*. 2011;33(12):1292–301. <https://doi.org/10.1111/j.1365-2036.2011.04663.x>.
55. Wang C, Lou C. Randomized controlled trial to investigate the effect of metal clips on early migration during stent implantation for malignant esophageal stricture. *Can J Surg*. 2015;58(6):378–82. <http://www.ncbi.nlm.nih.gov/pubmed/26574828>
56. Rieder E, Asari R, Paireder M, et al. Endoscopic stent suture fixation for prevention of esophageal stent migration during prolonged dilatation for achalasia treatment. *Dis Esophagus Off J Int Soc Dis Esophagus*. 2017;30(4):1–6. <https://doi.org/10.1093/dote/dow002>.
57. Shehab HM, Hakky SM, Gawdat KA. An endoscopic strategy combining mega stents and over-the-scope clips for the management of post-bariatric surgery leaks and fistulas (with video). *Obes Surg*. 2016;26(5):941–8. <https://doi.org/10.1007/s11695-015-1857-6>.
58. Diana M, Swanström LL, Halvax P, et al. Esophageal covered stent fixation using an endoscopic over-the-scope clip. Mechanical proof of the concept and first clinical experience. *Surg Endosc*. 2015;29(11):3367–72. <https://doi.org/10.1007/s00464-015-4078-0>.
59. Liu SYW, Wong SKH, Ng EKW. Novel oesophago-gastro-duodenal stenting for gastric leaks after laparoscopic sleeve gastrectomy. *Obes Res Clin Pract*. 2015;9(3):214–9. <https://doi.org/10.1016/j.orcp.2014.11.007>.
60. Puig CA, Waked TM, Baron THS, et al. The role of endoscopic stents in the management of chronic anastomotic and staple line leaks and chronic strictures after bariatric surgery. *Surg Obes Relat Dis*. 2014;10(4):613–7. <https://doi.org/10.1016/j.soard.2013.12.018>.